Holen Sie sich die Stockscreener-App
34.42
1.47%
0.50
Handel nachbörslich:
34.59
0.17
+0.49%
Schlusskurs vom Vortag:
$33.92
Offen:
$35
24-Stunden-Volumen:
4.38M
Relative Volume:
0.68
Marktkapitalisierung:
$3.87B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-37.01
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
+2.64%
1M Leistung:
+29.25%
6M Leistung:
+34.14%
1J Leistung:
-52.99%
1-Tages-Spanne:
$33.00
$35.25
1-Wochen-Bereich:
$30.85
$36.11
52-Wochen-Spanne:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
34.42 | 3.83B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Heatmap analysis for Viking Therapeutics Inc. and competitorsEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
How hedge fund analytics apply to Viking Therapeutics Inc. stockWeekly Market Report & High Yield Stock Recommendations - newser.com
Live market analysis of Viking Therapeutics Inc.2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
What makes Viking Therapeutics Inc. stock attractive to growth fundsTrade Risk Assessment & Proven Capital Preservation Methods - newser.com
Can trapped investors hope for a rebound in Viking Therapeutics Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Can Viking Therapeutics Inc. stock hit record highs again2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Can Viking Therapeutics Inc. (1VT) stock sustain margin levelsJuly 2025 Volume & Stepwise Swing Trade Plans - newser.com
Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? - MSN
Is Viking Therapeutics Inc. forming a bottoming baseWeekly Risk Report & Entry and Exit Point Strategies - newser.com
Why Viking Therapeutics Inc. stock attracts high net worth investorsEarnings Summary Report & Daily Oversold Stock Bounce Ideas - newser.com
Leerink Partners Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $118 - 富途牛牛
JP Morgan Lowers Price Target for Viking Therapeutics (VKTX) to $75 | VKTX Stock News - GuruFocus
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts - TipRanks
Viking Therapeutics (VKTX): Assessing Valuation After 36% Monthly Share Price Gain - simplywall.st
Viking Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges - TipRanks
Viking Bolts Higher; It's Moving At 'Lightning' Speed - Investor's Business Daily
Noteworthy Thursday Option Activity: VKTX, KODK, GEO - Nasdaq
Here's Why This Obesity Drug Company's Share Price Soared Today - AOL.com
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil - sharewise.com
Healthcare Stocks Show Mixed Moves As Companies Shift Strategies - Finimize
Why Is Viking Therapeutics Stock Rising Today? - Benzinga
Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside - Stocktwits
Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith) (VKTX) - Seeking Alpha
MASH, Metsera Deals Send Analysts Marauding to Viking - BioSpace
Viking Therapeutics: The Prime Target In The Obesity Gold Rush (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics stock price target raised by Cantor Fitzgerald on positive outlook - Investing.com
Viking Therapeutics (VKTX) Receives Updated Price Target from Mo - GuruFocus
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):